featured
Immunotherapy in RCC: An Overview of Key New Data From ASCO, Part 1
Interview by
Interview with
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- McDermott DF, Motzer RJ, Atkins MB, et al. Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 4507.
- Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813.
- Weinstock C, Maher VE, Zhang L, et al. FDA analysis of treatment beyond disease progression disease (PD) in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab vs. everolimus. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 4508.
- Escudier BJ, Motzer RJ, Sharma P, et al Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 4509.
Disclosure statements are available on the authors' profiles:
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.